Addition of abemaciclib to hormonal therapy for high-risk early breast cancer reduces recurrence by 25%, research suggests
Combining abemaciclib with hormonal therapy reduces the risk of cancer recurrence by 25% in patients with high-risk early hormone receptor positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) breast cancer, interim analysis of a phase III study has suggested.
Source: The Pharmaceutical Journal - Category: Drugs & Pharmacology Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Drugs & Pharmacology | HER2 | Hormonal Therapy | Hormones | Study